CN111714511A - Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia - Google Patents
Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia Download PDFInfo
- Publication number
- CN111714511A CN111714511A CN202010696763.XA CN202010696763A CN111714511A CN 111714511 A CN111714511 A CN 111714511A CN 202010696763 A CN202010696763 A CN 202010696763A CN 111714511 A CN111714511 A CN 111714511A
- Authority
- CN
- China
- Prior art keywords
- oligosaccharide
- preparation
- parts
- codonopsis pilosula
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 158
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 156
- 241000007126 Codonopsis pilosula Species 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 26
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 19
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 27
- 241000405414 Rehmannia Species 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 206010012289 Dementia Diseases 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 241000756943 Codonopsis Species 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 19
- 241000208340 Araliaceae Species 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229920005654 Sephadex Polymers 0.000 claims description 9
- 239000012507 Sephadex™ Substances 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000005227 gel permeation chromatography Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000001376 precipitating effect Effects 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000012384 transportation and delivery Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 12
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 abstract description 7
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 abstract description 7
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 abstract description 7
- 229960002646 scopolamine Drugs 0.000 abstract description 7
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 abstract description 5
- 230000007087 memory ability Effects 0.000 abstract description 3
- 201000004810 Vascular dementia Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002205 anti-dementic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000010171 animal model Methods 0.000 description 9
- 210000001320 hippocampus Anatomy 0.000 description 9
- 102100033639 Acetylcholinesterase Human genes 0.000 description 8
- 108010022752 Acetylcholinesterase Proteins 0.000 description 8
- 229940022698 acetylcholinesterase Drugs 0.000 description 8
- 238000012549 training Methods 0.000 description 6
- 230000009189 diving Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 208000020358 Learning disease Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 2
- 101150052852 Phlpp1 gene Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 2
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a codonopsis pilosula oligosaccharide composition which is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0-50 parts of rehmannia root oligosaccharide and 0-50 parts of red ginseng oligosaccharide; and discloses the application of the compound in preparing the preparation for preventing and treating senile dementia. The invention has the beneficial effects that: experiments prove that the codonopsis pilosula oligosaccharide and the composition of the codonopsis pilosula oligosaccharide, the rehmannia root oligosaccharide and the red ginseng oligosaccharide can obviously improve the learning and memory ability of mice with dementia caused by scopolamine, have anti-dementia activity, and can be used for preparing preparations for preventing and treating senile dementia including Alzheimer disease and vascular dementia.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a codonopsis pilosula oligosaccharide composition and application thereof in preparing a preparation for preventing and treating senile dementia.
Background
Senile dementia is a chronic neurodegenerative disease, which gradually destroys brain cells or the connection between brain cells, leads to the gradual loss of memory and cognitive function of patients, and even changes personality. Of these, Alzheimer's disease is the most common form of senile dementia, accounting for about 70%, especially among people over the age of 60-65. Worldwide, senile dementia has become one of the most major diseases threatening the health of the elderly. Therefore, it is important to find effective drugs for the treatment of dementia.
The codonopsis pilosula is used as a traditional Chinese medicine, and researches show that the codonopsis pilosula has anti-senile dementia activity, but the research on the anti-senile dementia effect of the codonopsis pilosula oligosaccharide serving as a main active component is still blank so far.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a codonopsis pilosula oligosaccharide composition and application thereof in preparing a preparation for preventing and treating senile dementia, wherein the senile dementia comprises Alzheimer disease and vascular dementia.
In order to achieve the purpose, the technical scheme provided by the invention is as follows: the codonopsis pilosula oligosaccharide composition is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0-50 parts of rehmannia root oligosaccharide and 0-50 parts of red ginseng oligosaccharide.
Further, the codonopsis pilosula oligosaccharide composition is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0 part of rehmannia root oligosaccharide and 0 part of red ginseng oligosaccharide.
Further, the codonopsis pilosula oligosaccharide composition is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 1-50 parts of rehmannia root oligosaccharide and 0 part of red ginseng oligosaccharide.
Further, the codonopsis pilosula oligosaccharide composition is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0 part of rehmannia root oligosaccharide and 1-50 parts of red ginseng oligosaccharide.
Further, the codonopsis pilosula oligosaccharide composition is prepared from the following raw materials in parts by weight: 50 parts of codonopsis pilosula oligosaccharide, 25 parts of rehmannia root oligosaccharide and 25 parts of red ginseng oligosaccharide.
Furthermore, the codonopsis pilosula oligosaccharide composition,
the preparation method of the codonopsis pilosula oligosaccharide comprises the following steps: mixing the codonopsis pilosula coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain radix Codonopsis crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified radix Codonopsis oligosaccharide with molecular weight below 5000 Da;
the preparation method of the rehmannia glutinosa oligosaccharide comprises the following steps: mixing rehmannia root coarse powder and 10 times of 95% ethanol according to the mass volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain rehmanniae radix crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified rehmanniae radix oligosaccharide with molecular weight below 5000 Da;
the preparation method of the red ginseng oligosaccharide comprises the following steps: mixing red ginseng coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain crude Ginseng radix Rubri oligosaccharide, and purifying by Sephadex gel chromatography to obtain purified Ginseng radix Rubri oligosaccharide with molecular weight below 5000 Da.
The second purpose of the invention is to provide the application of the codonopsis pilosula oligosaccharide composition in preparing a preparation for preventing and treating senile dementia.
Furthermore, the application of the codonopsis pilosula oligosaccharide composition in preparing a preparation for preventing and treating senile dementia is disclosed, wherein the preparation is a medicine, a food, a health-care product or a reagent, and the preparation for preventing and treating senile dementia is used for preventing, diagnosing, detecting, protecting, treating and researching dementia and directly related diseases thereof.
Furthermore, the application of the codonopsis pilosula oligosaccharide composition in preparing a preparation for preventing and treating senile dementia disease comprises the following administration modes: oral administration, nasal delivery, subcutaneous injection, intramuscular injection, intravenous injection or intravenous drip.
Further, the codonopsis pilosula oligosaccharide composition is applied to preparing a preparation for preventing and treating senile dementia, and the preparation is prepared from the following components in parts by weight: pill, capsule, tablet, syrup, sustained release preparation, controlled release preparation, injection preparation, suppository, gel, pellet, microemulsion, oral liquid, and spray.
The invention has the beneficial effects that: the codonopsis pilosula oligosaccharide composition and the application thereof in preparing the preparation for preventing and treating senile dementia have the advantages that the prepared medicine has good effect, the medicine is safe and effective, and no toxic or side effect exists; experiments prove that in the diving platform experiment, the groups of the codonopsis pilosula oligosaccharide, the codonopsis pilosula oligosaccharide and the rehmannia root oligosaccharide, the codonopsis pilosula oligosaccharide and the red ginseng oligosaccharide, and the codonopsis pilosula oligosaccharide and the rehmannia root oligosaccharide and the red ginseng oligosaccharide prolong the learning and memory latency of dementia mice caused by scopolamine; in Morris water maze experiments, radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide, radix Codonopsis oligosaccharide + Ginseng radix Rubri oligosaccharide, radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide + Ginseng radix Rubri oligosaccharide can reduce escape latency of mouse with dementia caused by scopolamine; the activity of acetylcholinesterase (AChE) in mouse hippocampus is determined, and the acetyl cholinesterase activity in mouse hippocampus caused by dementia can be reduced by the radix codonopsis oligosaccharide, the radix codonopsis oligosaccharide plus the rehmannia root oligosaccharide, the radix codonopsis oligosaccharide plus the red ginseng oligosaccharide, and the radix codonopsis oligosaccharide plus the rehmannia root oligosaccharide plus the red ginseng oligosaccharide.
Detailed Description
Example 1:
the ratio of the codonopsis pilosula oligosaccharide composition is shown in table 1.
In the codonopsis pilosula oligosaccharide composition, the active ingredients of the codonopsis pilosula oligosaccharide,
the preparation method of the codonopsis pilosula oligosaccharide comprises the following steps: mixing the codonopsis pilosula coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain radix Codonopsis crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified radix Codonopsis oligosaccharide with molecular weight below 5000 Da;
the preparation method of the rehmannia glutinosa oligosaccharide comprises the following steps: mixing rehmannia root coarse powder and 10 times of 95% ethanol according to the mass volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain rehmanniae radix crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified rehmanniae radix oligosaccharide with molecular weight below 5000 Da;
the preparation method of the red ginseng oligosaccharide comprises the following steps: mixing red ginseng coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain crude Ginseng radix Rubri oligosaccharide, and purifying by Sephadex gel chromatography to obtain purified Ginseng radix Rubri oligosaccharide with molecular weight below 5000 Da.
Example 2:
the influence of the codonopsis pilosula oligosaccharide and the composition thereof on the learning memory ability of the scopolamine-induced dementia mice in the diving platform experiment:
1. the experimental method comprises the following steps:
the experimental animals were divided into 7 groups: the method includes the steps of firstly, a blank group; a model group is formed; the group of thalidomide (positive drug); a codonopsis pilosula oligosaccharide group (groups 1-3 in table 1); fifthly, carrying out the combination of radix codonopsis oligosaccharide and rehmannia oligosaccharide (groups 4-6 in table 1); sixthly, a radix codonopsis oligosaccharide and red ginseng oligosaccharide group (7-9 groups in a table 1); codonopsis pilosula oligosaccharide + rehmannia glutinosa oligosaccharide + Red Ginseng oligosaccharide (groups 10-18 in Table 1), 15 each. The blank group and the model group are infused with tap water with the same amount, and the treatment groups are infused with the corresponding compatible extract solution of 250 mg/kg. From day 15, the mold was made with scopolamine hydrobromide and the behavioral experiments were performed.
The diving platform experiment is carried out in a 320X 225X 330 mm reflection box which is divided into 6 cells, and copper grids are laid at the bottom of each cell for connecting current. A small platform is arranged at the upper left corner of each chamber and is called a safety zone. Before the bench jump experiment starts, the experimental animal freely moves in the box for 3 min, then alternating current (32V) is switched on, the experimental animal feels stimulation, the experimental animal does not jump to a safety zone within 5 min, an experimenter actively leads the experimental animal to the safety zone, and the mouse is tested and tested after 24 hours. The experimental animal is put on the safety zone and the current is switched on at the same time, and the time for the experimental animal to jump down the safety zone for the first time is recorded, so that the memory capacity of the experimental animal is reflected. Donepezil (positive drug), radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide, radix Codonopsis oligosaccharide + Ginseng radix Rubri oligosaccharide, radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide + Ginseng radix Rubri oligosaccharide, and the composition is administered by intragastric administration 40 min before the start of the experiment. After 30min, the experimental animals except the blank group were molded with scopolamine hydrobromide (2 mg/kg), and after 10 min, the bench jump experiment was performed.
2. The experimental results are as follows:
the learning and memory latencies of the model mice were significantly reduced compared to the blank group (P<0.01). Compared with the model group, the groups of radix codonopsis oligosaccharide, radix codonopsis oligosaccharide and rehmannia root oligosaccharide, radix codonopsis oligosaccharide and red ginseng oligosaccharide can obviously prolong the learning and memory latency of the model mice to different degreesP<0.05 orP<0.01). The influence of the codonopsis pilosula oligosaccharide and the composition thereof on the mouse diving platform experiment of the learning and memory disorder model caused by scopolamine is shown in table 2.
TABLE 2
Note: p <0.01 compared to blank group; compared to the model group, # P <0.05, # P < 0.01.
Example 3:
the influence of the codonopsis pilosula oligosaccharide and the composition thereof on the learning memory ability of a mouse with dementia caused by scopolamine in a Morris water maze experiment:
1. the experimental method comprises the following steps:
the experimental device is a circular water tank with the length of 80 cm and the height of 40 cm, clean tap water with the depth of 18.5 cm is arranged in the tank, the tank is divided into four areas I, II, III and IV at the temperature of 25 ℃, and a safety platform with the length of 10 cm and the height of 17.5 cm is arranged in the IV area. White pigment is scattered into the pool and is stirred uniformly so as to be used for shielding the safety platform. The environmental and reference systems should remain unchanged throughout the experiment.
The experiment was carried out for a period of 5 days. The first 3 days are training experiments, training is carried out for 4 times every day, the training time is 120 s every time, the time from entering water to jumping to the safety platform is the escape latency, if the training is found within 120 s, the safety platform stays on the platform for 10 s, if the training is not found within 120 s, an experimenter leads the safety platform to stay on the platform for 10 s, and the escape latency is set to be 120 s. And the 4 th day is a positioning navigation test experiment, the test process is consistent with that of the training experiment, and the time (latency) for the mouse to find the safe platform is recorded. On the 5 th day of the experiment, the safety console was removed, and the percentage of residence time and the percentage of movement distance in the area of the safety console in the mouse 120 s were recorded, thereby detecting the change in spatial memory.
2. The experimental results are as follows:
the percent residence time in the target quadrant and the percent swimming distance in the plateau quadrant for the model group mice were significantly reduced compared to the normal group (P)<0.01). Compared with the model group, the radix Codonopsis oligosaccharide, radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide, radix Codonopsis oligosaccharide + Ginseng radix Rubri oligosaccharide, radix Codonopsis oligosaccharide + rehmanniae radix oligosaccharide + Ginseng radix Rubri oligosaccharide can significantly increase the residence time percentage (P) of the model mouse in the target quadrant<0.05 or P<0.01); increasing percent swimming distance in platform quadrant (P)<0.05 or P<0.01). The influence of different compatibility of the Qing' e prescription on the mouse Morris water maze experiment of the model with learning and memory disorder caused by Scop is shown in the table 3,
。
TABLE 3
Note: p <0.05, P <0.01, compared to blank; compared to the model group, # P <0.05, # P < 0.01.
Example 4:
the influence of the codonopsis pilosula oligosaccharide and the composition thereof on the activity of acetylcholinesterase in hippocampus of mouse with dementia caused by scopolamine:
1. the experimental method comprises the following steps:
after the completion of the water maze experiment, the mouse is dislocated and killed, the hippocampus is taken out, the blood stain on the surface of the hippocampus is washed, the blood and the redundant tissue are removed, the mass of the hippocampus is precisely weighed after the hippocampus is wiped dry by filter paper, 4 ℃ physiological saline is added according to the proportion that the mass (g) and the volume (mL) are 1:9, the mixture is ground into 10 percent homogenate, and the supernatant is taken for standby application after centrifugation. The acetylcholinesterase activity was measured according to the kit instructions.
2. The experimental results are as follows:
the acetylcholinesterase activity in the hippocampus of the model group mice is significantly increased compared with that of the normal group (P<0.01); compared with the model group, the radix codonopsitis oligosaccharide, radix codonopsitis oligosaccharide and rehmannia root oligosaccharide, radix codonopsitis oligosaccharide and red ginseng oligosaccharide, radix codonopsitis oligosaccharide and rehmannia root oligosaccharide and red ginseng oligosaccharide can obviously reduce the activity of acetylcholinesterase (P<0.01). The effects of different combinations on AChE and BDNF in hippocampus of Scop-induced learning and memory disorder model mice are shown in Table 4
TABLE 4
Note: p <0.05, P <0.01, compared to blank; compared to the model group, # P <0.05, # P < 0.01.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The codonopsis pilosula oligosaccharide composition is characterized by being prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0-50 parts of rehmannia root oligosaccharide and 0-50 parts of red ginseng oligosaccharide.
2. The codonopsis pilosula oligosaccharide composition according to claim 1, which is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0 part of rehmannia root oligosaccharide and 0 part of red ginseng oligosaccharide.
3. The codonopsis pilosula oligosaccharide composition according to claim 1, which is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 1-50 parts of rehmannia root oligosaccharide and 0 part of red ginseng oligosaccharide.
4. The codonopsis pilosula oligosaccharide composition according to claim 1, which is prepared from the following raw materials in parts by weight: 1-99 parts of codonopsis pilosula oligosaccharide, 0 part of rehmannia root oligosaccharide and 1-50 parts of red ginseng oligosaccharide.
5. The codonopsis pilosula oligosaccharide composition according to claim 1, which is prepared from the following raw materials in parts by weight: 50 parts of codonopsis pilosula oligosaccharide, 25 parts of rehmannia root oligosaccharide and 25 parts of red ginseng oligosaccharide.
6. The Codonopsis oligosaccharide composition of any one of claims 1-5, wherein the oligosaccharide is selected from the group consisting of,
the preparation method of the codonopsis pilosula oligosaccharide comprises the following steps: mixing the codonopsis pilosula coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain radix Codonopsis crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified radix Codonopsis oligosaccharide with molecular weight below 5000 Da;
the preparation method of the rehmannia glutinosa oligosaccharide comprises the following steps: mixing rehmannia root coarse powder and 10 times of 95% ethanol according to the mass volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain rehmanniae radix crude oligosaccharide, and purifying with Sephadex gel chromatography to obtain purified rehmanniae radix oligosaccharide with molecular weight below 5000 Da;
the preparation method of the red ginseng oligosaccharide comprises the following steps: mixing red ginseng coarse powder with 10 times of 95% ethanol according to the mass-volume ratio, carrying out reflux extraction for 2 times at 90 ℃ in a water bath for 1 hour each time, collecting decoction dregs, adding 10, 8 and 8 times of water by weight of the decoction dregs into the collected decoction dregs, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract under reduced pressure at 50 ℃ and 60rpm to 1/4 volumes to obtain concentrated solution; adding 95% ethanol into the concentrated solution until the final concentration of ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 50 deg.C and 60rpm under reduced pressure to volatilize ethanol to obtain crude Ginseng radix Rubri oligosaccharide, and purifying by Sephadex gel chromatography to obtain purified Ginseng radix Rubri oligosaccharide with molecular weight below 5000 Da.
7. Use of the Codonopsis oligosaccharide composition of any one of claims 1-5 in the preparation of a formulation for the prevention and treatment of Alzheimer's disease.
8. The use of the Codonopsis pilosula oligosaccharide composition as claimed in claim 7 for the preparation of a preparation for the prevention and treatment of Alzheimer's disease, wherein the preparation is a medicament, food, health product or reagent, and the preparation for the prevention and treatment of Alzheimer's disease is for the prevention, diagnosis, detection, protection, treatment and research of dementia and its directly related diseases.
9. The use of the Codonopsis pilosula oligosaccharide composition as claimed in claim 8 for the preparation of a formulation for the prevention and treatment of Alzheimer's disease, wherein the medicament is administered by: oral administration, nasal delivery, subcutaneous injection, intramuscular injection, intravenous injection or intravenous drip.
10. The use of the codonopsis pilosula oligosaccharide composition according to claim 9 in the preparation of a preparation for preventing and treating senile dementia, wherein the preparation is in the form of: pill, capsule, tablet, syrup, sustained release preparation, controlled release preparation, injection preparation, suppository, gel, pellet, microemulsion, oral liquid, and spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696763.XA CN111714511A (en) | 2020-07-20 | 2020-07-20 | Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696763.XA CN111714511A (en) | 2020-07-20 | 2020-07-20 | Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111714511A true CN111714511A (en) | 2020-09-29 |
Family
ID=72572879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010696763.XA Pending CN111714511A (en) | 2020-07-20 | 2020-07-20 | Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111714511A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306463A (en) * | 2021-12-07 | 2022-04-12 | 兰州大学 | Oligosaccharide composition extracted from Chinese medicinal materials, and its preparation method and application |
| CN114306372A (en) * | 2021-12-07 | 2022-04-12 | 兰州大学 | Polysaccharide extract of traditional Chinese medicine composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111135206A (en) * | 2020-03-02 | 2020-05-12 | 兰州大学 | Application of codonopsis pilosula oligosaccharide in preparation of anti-anemia drugs |
-
2020
- 2020-07-20 CN CN202010696763.XA patent/CN111714511A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111135206A (en) * | 2020-03-02 | 2020-05-12 | 兰州大学 | Application of codonopsis pilosula oligosaccharide in preparation of anti-anemia drugs |
Non-Patent Citations (1)
| Title |
|---|
| 郑晓萍: "青娥方及复方党参方的药学研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306463A (en) * | 2021-12-07 | 2022-04-12 | 兰州大学 | Oligosaccharide composition extracted from Chinese medicinal materials, and its preparation method and application |
| CN114306372A (en) * | 2021-12-07 | 2022-04-12 | 兰州大学 | Polysaccharide extract of traditional Chinese medicine composition and preparation method and application thereof |
| CN114306372B (en) * | 2021-12-07 | 2023-10-31 | 兰州大学 | Polysaccharide extract of traditional Chinese medicine composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078460B (en) | Traditional Chinese medicine for preventing and treating Alzheimer disease and preparation method thereof | |
| CN111714511A (en) | Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia | |
| CN101919913B (en) | Composition with effect of treating rheumatoid arthritis | |
| CN108210818B (en) | Pharmaceutical composition for preventing and treating neurodegenerative diseases and preparation method and application thereof | |
| CN102727619B (en) | Medicinal composition treating fatty liver and preparations thereof | |
| CN110742972B (en) | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation | |
| CN108785357A (en) | A kind of masticinic acid and myrrh terpene compatible composition and its preparation method and application | |
| CN102772469B (en) | Medicine composition used for preventing or treating senile dementia | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN101002857B (en) | Traditional Chinese medicine composition, and its use | |
| CN103070927A (en) | New usages of lotus plumule and alkaloid thereof and derivative thereof | |
| CN101279018B (en) | Chinese medicine naoxueshu preparations | |
| CN102727620A (en) | Medicinal composition treating fatty liver and preparation method thereof | |
| CN102188471A (en) | Pharmaceutical composition for treating Alzheimer disease symptom and its preparation method | |
| CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
| CN107854656A (en) | A kind of Chinese traditional medicines depressing lipid composition and its production and use | |
| CN102940621B (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis | |
| CN102940668A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN105688031A (en) | Application of compound traditional Chinese medicine preparation in treatment of Alzheimer's disease | |
| CN107854620B (en) | Traditional Chinese medicine composition for improving cognitive dysfunction after brain injury and application thereof | |
| AU2021100051A4 (en) | Antitumor formula and extraction method thereof | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN100355447C (en) | Compound preparation for treating liver fibrosis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200929 |
|
| RJ01 | Rejection of invention patent application after publication |